<DOC>
	<DOCNO>NCT00325780</DOCNO>
	<brief_summary>This study long-term follow-up protocol patient participate study NK-104-3.01EU study NK-104-3.02EU .</brief_summary>
	<brief_title>Long-Term Extension Study Pitavastatin Patients With Primary Hypercholesterolemia Combined Dyslipidemia</brief_title>
	<detailed_description>Patients NK-104-3.01EU NK-104-3.02EU study continue receive either pitavastatin comparator statin 1 year .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Patients complete 12 week treatment Study NK104301 ( NCT00249249 ) NK104302 ( NCT00309777 ) Patients develop treatment emergent , opinion investigator , related adverse event ( AE ) clinical significance investigator uncomfortable continue patient therapy pitavastatin . Patients follow fat cholesterol restrictive diet . Any condition may cause secondary dyslipidemia reassess begin followup study . Uncontrolled diabetes mellitus reassess begin followup study . Abnormal pancreatic , liver , renal function Abnormal serum ALAT/SGPT/ALT , ASAT/SGOT/AST , creatine kinase ( CK ) prespecified level Significant heart disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Kowa</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>pitavastatin</keyword>
	<keyword>NK-104</keyword>
	<keyword>Hypercholesterolemia combine dyslipidemia</keyword>
</DOC>